.-Analysis of an acid extract of the striatum of the rhesus monkey revealed that the molar ratio of dynorphin A(1-8)-sized material and dynorphin (A(1-17)-sized material is approximately I:1. In addition, the molar ratios of the dynorphin A-related end products to both dynorphin B(l-13)-sized material and alpha-neo-endorphin-sized material were approximately 1:1. Fractionation of an acid extract of the substantia nigra by gel filtration and reverse phase HPLC revealed the following molar ratios for pro-dynorphin-related end products. The molar ratio of dynorphin A(1-8) to dynorphin A(1-17) is approximately 6:1. The molar ratios of dynorphin A-related end products to dynorphin B(1-13) and alpha-neo-endorphin were approximately 0.5 and 0.8, respectively. Comparisons between proteolytic processing patterns of pro-dynorphin in the striatum and the substantia nigra of the rhesus monkey are considered. In addition, comparisons between pro-dynorphin processing in the substantia nigra of the rhesus monkey and the substantia nigra of the rat [4] are discussed.
SEQUENCES of the opioid peptides, alpha-neo-endorphin I1 l l, d ynorphin A(1-17) [7] , and dynorphin B(1-13) [5, 14] are all contained within the sequence of the polyprotein, prodynorphin [10] . Differential proteolytic processing of this precursor at sites of either paired basic amino acids (i.e., Lys-Arg) or at a single Arg residue can give rise to a variety of opioid end products. In addition to the peptides listed above, the following opioid peptides have also been detected in pro-dynorphin systems: beta-neo-endorphin [18] , dynorphin A(l-8) [17, 24] and leumorphin ( [19, 35] ; the COOHterminal extended form of dynorphin B(l-13)).
Several anatomical studies on the distribution of prodynorphin-related end products in the brain of the rat indicate that there is not just a single pro-dynorphin circuit in the central nervous system, but rather several independent prodynorphin networks which are distributed widely throughout the brain [12, 16, 26, 27, 28, 29, 30, 31] . Accordingly, studies on the steady state levels of pro-dynorphin-related end products in the central nervous system of the rat [2, 25, 32] indicate that pro-dynorphin can undergo differential posttranslational processing to yield distinct sets of end products in different regions of the rat brain. However, because of the complex anatomical distribution of pro-dynorphin perikarya and terminals in the central nervous system, it is necessary to go beyond regional analysis and focus on anatomically well defined pro-dynorphin networks. This study will consider processing of pro-dynorphin in the striato-nigral pathway.
Anatomical studies on the brain of the rat have clearly established that pro-dynorphin perikarya can be localized in the caudate-putamen (i.e., striatum; [12, 29, 30] ). Independently, two groups have demonstrated by chemical lesion [26] and surgical lesion [34] experiments that pro-dynorphin perikarya located in the striatum project to the substantia nigra. A comparison of the steady state levels of dynorphin A-related material in the substantia nigra and the posterior pituitary, the terminal field for magnocellular neurons originating in the supraoptic and paraventricular nuclei [27, 28, 31] , revealed that the molar ratio of dynorphin A(1-8) to dynorphin A(l-17) in the posterior pituitary is approximately l: l, whereas the molar ratio of these peptides in the substantia nigra is approximately 16: l [4] . Thus, the proteolytic processing events that occur in the rat striato-nigral pathway result in the conversion of dynorphin A(l-17), a highly selective kappa agonist, to dynorphin A(l-8), an opioid with mixed selectively for kappa and delta receptors [1, 3, 20, 22, 23, 33] . Since pro-dynorphin is differentially processed in two anatomically distinct systems within the rat brain, the present study was done to determine whether similar processing patterns for pro-dynorphin could be observed in the substantia nigra of a primate, the rhesus monkey.
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METHOD
For these experiments the striatum (wet weight: 4.8 g) and the substantia nigra (wet weight: 0.6 g) were collected from an adult postmenopausal female rhesus monkey (species: Macaque mulatta), obtained from the Primate Research Center at the University of Michigan School of Medicine. The tissues were separately extracted in ten volumes of acetone:0. I N HCI (3: I). The homogenate was centrifuged for 45 min at 12,000 rpm, and the supernatant was concentrated under vacuum (Savant Speed Vac). The dried extract was dissolved in a volume of 10% formic acid and fractionated by gel filtration on a Sephadex G-50 superfine column (Pharmacia) equilibrated in 10% formic acid which contained 100 tzg/ml bovine serum albumin. Following gel filtration, aliquots of the column fractions were concentrated under vacuum and analyzed by radioimmunoassay. The recovery of immunoreactivity following gel filtration averaged 85%.
Radioimmunoassays for dynorphin A(1-17), dynorphin A(1-8), dynorphin B(1-13), and alpha-neo-endorphin were done following the method described by Ghazarossian et al. [6] with some modifications. All primary antisera were raised in rabbits as described by Khachaturian et al. [12] . Synthetic dynorphin A(1-17), dynorphin A(I-8), and alpha-neoendorphin were purchased from Bachem (Torrance, CA). Synthetic dynorphin B(1-13) was provided by Dr. Richard Houghton (Scripps Institute). Peptides were iodinated by the chloramine T procedure. For dynorphin A(1-17) and dynorphin A(1-8) assays the RIA buffer consisted of methanol/0.1 N HCI (3:11 and 150 mM sodium phosphate, 0.1% bovine serum albumin, 0. l% triton X-100, pH 8.2 buffer in a ratio of 1:2.5. For dynorphin B(1-13) and alpha-neo-endorphin assays, the RIA buffer consisted of methanol/0.1 N HCI (3:1) and 150 mM sodium phosphate, 1% bovine serum albumin, 0.1% triton X-100, pH 7.5 buffer, in a ratio of 1:2.5. For all RIAs, the final reaction volume was 200 ~zl. RIAs were run at 4°C for 18-24 hr and terminated by the double antibody procedure using goat anti-rabbit IgG. The primary antisera used in these assays had the following specificities.
Dynorphin A( I-17)
Antisera No. 54 (final concentration: 1:12,000) was raised against synthetic dynorphin A(I-17). This antisera has 80% molar crossreactivity with dynorphin A(1-13), but less than 0.1% molar crossreactivity with dynorphin A(1-8), dynorphin B(1-13), alpha-neo-endorphin and leucine enkephalin. This antisera crossreacts in a parallel manner with 11K, 6K, and 4K forms of dynorphin A-related immunoreactivity [4] . The midpoint of this assay is 70 fmol/tube.
Dynorphin A( I--8)
Antisera No. 73 (final concentration: 1:5,000) was raised against synthetic dynorphin A(1-8). This antisera has I% molar crossreactivity with dynorphin A(1-17) and less than 0.1% molar crossreactivity with alpha-neo-endorphin, dynorphin B(1-13) and leucine enkephalin. This antisera does not appear to crossreact with high molecular weight forms of dynorphin A. The midpoint of this assay is 90 fmol/tube.
Dynorphin B( I-13)
Antisera No. 94 (final concentration: 1:4,000) was raised against synthetic dynorphin B(1-13). This antisera has less than 0.1% molar crossreactivity with dynorphin A(I-17), dynorphin A(I-81. alpha-neo-endorphin or leucine enkephalin. However, this antisera does crossreact in a parallel manner with 6K and 4K forms of dynorphin B-related material. The midpoint of this assay is 60 fmol/tube.
A Ipha-Neo-Endorphin
Antisera No. 59 (final concentration: 1:4,000) was raised against synthetic alpha-neo-endorphin. This antisera has 1% molar crossreactivity with beta-neo-endorphin, and less than 0.1% molar crossreactivity with dynorphin A(I-17), dynorphin A(1-8), alpha-neo-endorphin or leucine enkephalin. This antisera does not appear to crossreact with any high molecular weight forms of alpha-neo-endorphin-related material. The midpoint of this assay is 70 fmol/tube. Peaks of immunoreactivity isolated by gel filtration were separately analyzed by reverse phase high performance liquid chromatography (HPLC) on a Beckman ODS ultrasphere 5 micron column (4.6 mm×25 cm). The column was eluted with a 4 to 32% nonlinear gradient of acetonitrile in 0.1% trifluoacetic acid (Pierce). The recovery of immunoreactivity from this column averaged 80%.
RESULTS

Steady State Levels of Pro-Dym)rphin-Related Products in the Striatum
Anatomical and biochemical analyses of the striato-nigral pro-dynorphin network have primarily focused on the rat system [4, 12, 26, 34] . Anatomical studies of the rhesus monkey central nervous system indicate that pro-dynorphin perikarya can also be demonstrated in the caudate nucleus of this species [13] . In addition, pro-dynorphin-related immunoreactivity is primarily concentrated in the zona reticulata of the substantia nigra of this species with a distribution similar to what has already been reported for the rat substantia nigra [12] . The apparent similarities between the well defined striato-nigral pro-dynorphin pathway in the rat and the apparent striato-nigral pathway in the rhesus monkey prompted us to compare the steady state levels of prodynorphin products in the striatum (caudate and putamen) and substantia nigra of the rhesus monkey. Furthermore, additional studies on the processing of pro-dynorphin in the brain of a primate are of interest, given the observation that the concentration of pro-dynorphin-related products in the human substantia nigra is particularly high relative to other regions of the brain [15] .
Analysis of an extract of the striatum of the rhesus monkey by gel filtration chromatography in conjunction with radioimmunoassay analyses is shown in Fig. 1 . Four peaks of dynorphin A-related material were detected in this extract (Fig. 1A) . The dynorphin A(1-17) RIA detected two minor peaks (K,,.=0.30 and 0.43, respectively) and one major peak (K,,=0.67). The minor peaks have apparent molecular weights of approximately 6K and 4K, respectively, and are similar to peaks of immunoreactivity detected with this RIA (Table 1) . These results are in contrast to analyses of the rat striatum where the levels of dynorphin A(1-8)-sized material range from 9 to 16 fold higher than the dynorphin A(I-17)-sized material ( [25, 32] ; Dores, unpublished data).
The dynorphin B(1-13) RIA also detected multiple peaks of immunoreactivity (Fig. IB) . Two minor peaks of immunoreactivity (K,,=0.28 and 0.44) correspond to material with apparent molecular weights of 6K and 4K, respectively. The major peak of immunoreactivity (Kay=0.74) has the same apparent molecular weight as synthetic porcine dynorphin B(1-13). In this tissue the molar ratio of dynorphin B(l-13)-sized material to dynorphin A (dynorphin A(I-8)-+ dynorphin A(1-17)-sized material) is approximately 1:1. The alpha-neo-endorphin RIA detected a single peak of immunoreactivity (K,~v=0.77) and this peak has the same apparent molecular weight as synthetic porcine alpha-neoendorphin (Fig. 1B) . The alpha-neo-endorphin-sized material is also present in roughly equimolar amounts with the dynorphin A-related material (Table 1) .
Steady State Levels of Pro-Dynorphin-Related End Products in the Substantia Nigra
The preceding section dealt with a consideration of the pro-dynorphin-related products in the striatum (Fig. 1 and Table 1 ). Although the striatum contains pro-dynorphin perikarya which are presumed to project to the substantia nigra, it is clear from anatomical studies on both the rat [12] and rhesus monkey [13] striatum that this region of the brain not only contains perikarya, but also contains fibers of passage as well as local terminal fields. By contrast, the substantia nigra is devoid of pro-dynorphin perikarya and con-'ains only terminal fields, thus the forms of pro-dynorphin-'lated end products detected in this area represent the final ~cessed forms which are presumably being stored for secretion.
Analysis of an extract of the substantia nigra of the rhesus monkey are presented in Figs. 2 and 3 and Table 1 . Gel filtration of this extract ( Fig. 2A ) followed by analysis with the dynorphin A(I-17) RIA detected two minor peaks of dynorphin A-related immunoreactivity (K,, =0.45 and 0.67). The former peak eluted with an apparent molecular weight of 4K and the latter peak has the same apparent molecular weight as synthetic porcine dynorphin A(1-17). The major peak of dynorphin A-related material in this extract was detected with the dynorphin A(1-8) RIA. This peak of immunoreactivity (Kav=0.85) has the same apparent molecular weight as synthetic dynorphin A(1-8). The identities of the dynorphin A(1-17)-sized material and the dynorphin A(1-8)-sized material isolated in Fig. 2A were confirmed by reverse phase HPLC analysis (Fig. 3B) . The molar ratios of these dynorphin A-related end products are summarized in Table 1 . In the rhesus monkey substantia nigra the molar ratio of dynorphin A(1-8) to dynorphin A(1-17) is approximately 6: 1.
Analysis of the extract of the substantia nigra with the dynorphin B(1-13) RIA also revealed multiple peaks of immunoreactivity (Fig. 2B) . Two minor peaks (K~,v=0.31 and 0.45) and a major peak (Kay=0.73) were detected. The latter peak has the same apparent molecular weight as synthetic dynorphin B(1-13). Analysis of this peak of immunoreactivity by reverse phase HPLC (Fig. 3A) indicated that the dynorphin B(1-13)-sized material migrated with the same retention time as synthetic porcine dynorphin B(!-13). The molar ratio of dynorphin B(1-13) to dynorphin A(dynorphin A(1-17) + dynorphin A (1-8) ) is approximate 0.5:1 ( Table 1) .
Analysis of the extract of the substantia nigra with the alpha-neo-endorphin RIA (Fig. 2B ) revealed a single peak of immunoreactive material (K,v=0.77) with the same apparent molecular weight as synthetic porcine alpha-neo-endorphin. The identity of this peak was confirmed by reverse phase HPLC analysis (Fig. 3A) . The molar ratio of alpha-neoendorphin to dynorphin A in this tissue is approximately 0.8:1.
DISCUSSION
The action of opiates on the nigro-striatal dopaminergic pathway is a very complex issue (for review see [21] ). A recent study indicates that administration of opioid peptides at the level of the zona reticulata of the substantia nigra appears to influence the activity of the dopaminergic perikarya in the zona compacta of the substantia nigra [8] . Accordingly, anatomical studies of the zona reticulata of the rat and rhesus monkey brain [12, 13] indicate that this region of the substantia nigra contains an extensive pro-dynorphin terminal field. Lesion studies have established that in the rat brain pro-dynorphin perikarya originating in the striatum project to the substantia nigra [26, 34] . Although it appears that the major pro-dynorphin projection to the substantia nigra comes from the striatum, the possibility of extrastriatai projections can not be eliminated at this time. With the detection of pro-dynorphin perikarya in the striatum of the rhesus monkey and the extensive pro-dynorphin terminal field in the substantia nigra of this species, it appears highly likely that a pro-dynorphin striato-nigral network is also present in the rhesus monkey.
In the present study we examined the steady state levels of pro-dynorphin-related products in the striatum and substantia nigra of the rhesus monkey. Both regions of the rhesus monkey brain contain dynorphin A(1-17)-, dynorphin A(I-8)-, dynorphin B(I-13)-, and alpha-neo-endorphin-sized material which appear to be chromatographically identical to the porcine forms of these pro-dynorphin opioid end products. Sequence analysis of the pro-dynorphin gene obtained from a human genomic DNA library [9] indicates that in this primate the opioid peptide sequences are identical to the porcine sequences [10] . Thus in mammals as diverse as rodent. porcine and primate the opioid sequences of prodynorphin are highly conserved.
In the striatum of the rhesus monkey roughly equimolar amounts of dynorphin A (dynorphin A(1-17) + dynorphin A(1-8)), dynorphin B(I-13), and alpha-neo-endorphin were detected. One of the striking features of the rhesus monkey striatum is the roughly equimolar amounts of dynorphin A( 1-17)-and dynorphin A(1-8)-sized material. This is in contrast to the striatum of the rat where the predominant form of dynorphin A is dynorphin A(I-8) [25, 32] . Furthermore, although high molecular weight forms of dynorphin A-related material and dynorphin B-related material were detected, the predominant forms of pro-dynorphin products in the striatum were the low molecular opioid peptides.
In the substantia nigra of the rhesus monkey proteolytic processing of pro-dynorphin has proceeded even further than in the striatum. Although high molecular weight forms of dynorphin A-related and dynorphin B-related material were detected in the substantia nigra, these forms were present in a lower percentage than in the striatum. These data suggest that proteolytic processing proceeds to near completion in the substantia nigra. Further evidence of the extent of proteolytic processing in the substantia nigra is seen in the molar ratio of dynorphin A(1-17) and dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) . In the striatum these forms were present in roughtly a 1:1 ratio, whereas in the substantia nigra there is 6 fold more dynorphin A(1-8) as compared to dynorphin A (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) . The increase in the levels of dynorphin A(1-8) in the substantia nigra as compared to the striatum and the accompanying shift in opiate receptor specificity of dynorphin A(1-8) may have functional significance. It is noteworthy, however, that the ratio of the forms of dynorphin A in the rhesus monkey substantia nigra is not as extreme as the ratio of these forms in the rat substantia nigra, where there is approximately 16 fold more dynorphin A(1-8) as compared to dynorphin A(1-17) [4] .
Another difference between the steady state levels of pro-dynorphin products in the striatum and substantia nigra of the rhesus monkey is that the molar ratio of dynorphin A, dynorphin B(1-13), and alpha-neo-endorphin were approximately 1:1 in the striatum, however, in the substantia nigra there were approximately 20% and 50% less of alpha-neoendorphin and dynorphin B(1-13), respectively, as compared to dynorphin A end products. The minor drop in alpha-neo-endorphin may indicate a conversion to betaneo-endorphin. The 50% drop in dynorphin B(1-13) relative to dynorphin A end products may reflect a conversion of the former to leucine enkephalin. The use of a biosynthetic labelling paradigm will be required in order to properly evaluate these possibilities.
Finally, the results reported in this study reflect the steady state levels of pro-dynorphin products in the adult female rhesus monkey. Further studies are needed on animals of both sexes at different periods in ontogeny in order to obtain a better understanding of pro-dynorphin processing in primates.
